It’s that time of year again, the time when all the top firms that we cover here at 24/7 Wall St. start to make their stock picks and prognostications for 2016. This not only gives investors a little bit of a head start on year-end portfolio reshuffling, but it also gives them a look at what the overall macro thoughts for the coming year are at the big brokerages and banks.
The analysts at Cowen have gone through the fundamentals and the balance sheets, and they have produced five outstanding health care picks that include devices, biotech and specialty pharmaceuticals. We picked one of the biotechs with the biggest upside to go along with the other two best ideas.
This is one the best idea biotech stock picks with the biggest upside to the Cowen price target. Celldex Therapeutics Inc. (NASDAQ: CLDX) is developing targeted therapeutics to address devastating diseases for which available treatments are currently inadequate. The company’s pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body’s immune response.
Earlier this year, the company received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its drug Rintega, and recently it posted strong two-year survival clinicals when used with Roche’s Avastin. Cowen is bullish on the name and cites the company’s very attractive pipeline of first-in-class and fully owned oncology assets, and the firm expects major pipeline updates to drive stock appreciation in 2016.
Cowen also feels that Celldex’s rindopepimut is underappreciated as peptide vaccines, and in general such therapeutic strategies have fallen out of favor as investors focus on hot immuno-oncology fields like checkpoint inhibitors, engineered T cells and novel receptors. Cowen also thinks the Phase 2 data is being overlooked, and that the ACT IV study is stopped early next year for efficacy. The firm is ultimately confident in Phase 3 success.
The Cowen price target for the stock is $28, and the Thomson/First Call consensus target is even higher at $34. The stock closed on Wednesday at $15.30.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.